Carcinoma que surge do epitélio nasofaríngeo. Inclui os seguintes tipos: carcinoma espinocelular queratinizante, carcinoma não queratinizante (diferenciado e indiferenciado), carcinoma espinocelular basaloide e adenocarcinoma papilar.
Introdução
O que você precisa saber de cara
Carcinoma que surge do epitélio nasofaríngeo. Inclui os seguintes tipos: carcinoma espinocelular queratinizante, carcinoma não queratinizante (diferenciado e indiferenciado), carcinoma espinocelular basaloide e adenocarcinoma papilar.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Multigenic/multifactorial, Not applicable.
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL (RELA/p65 and NFKB1/p50) dimers in the cytoplasm by masking their nuclear localization signals (PubMed:1493333, PubMed:36651806, PubMed:7479976). On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription (PubMed:7479976, PubMed:7628694, PubMed:7796813, PubMed:7878466)
CytoplasmNucleus
Ectodermal dysplasia and immunodeficiency 2
A form of ectoderma dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. This form of ectodermal dysplasia is associated with decreased production of pro-inflammatory cytokines and certain interferons, rendering patients susceptible to infection. EDAID2 inheritance is autosomal dominant.
Medicamentos e terapias
Mecanismo: Thymidylate synthase inhibitor
Mecanismo: Thymidylate synthase inhibitor
Mecanismo: Epidermal growth factor receptor erbB1 inhibitor
Mecanismo: Vascular endothelial growth factor receptor 2 inhibitor
Mecanismo: Tubulin inhibitor
Variantes genéticas (ClinVar)
51 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 48 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
15 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Carcinoma nasofaríngeo
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
17 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
1.063 ensaios clínicos encontrados, 31 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 10.542
PRELID2 promotes the progression of nasopharyngeal carcinoma by positively regulating the TXNDC12-GSH-GPX4 axis and inhibiting ferroptosis.
Nasopharyngeal carcinoma (NPC) treatment is challenged by advanced metastasis, high recurrence rates, and resistance to both radiotherapy and chemotherapy. PRELI domain-containing protein 2 (PRELID2) is overexpressed in cancers and linked to poor prognosis, but its role in NPC remains unclear. We utilized public datasets to analyze the expression characteristics and clinical prognostic significance of PRELID2 in NPC. The expression of PRELID2 in NPC cell lines was validated through Western blotting and quantitative reverse transcription PCR (qRT-PCR). The effects of PRELID2 on NPC cell proliferation, migration, and invasion were assessed using in vitro functional assays, such as CCK-8, colony formation, Transwell, wound healing assays, and an in vivo subcutaneous xenograft tumor model in nude mice. Downstream mechanisms were investigated through RNA-seq and rescue experiments. Both mRNA and protein levels of PRELID2 were elevated in NPC cells, and associated with poorer survival. In vitro experiments demonstrated that overexpression of PRELID2 significantly enhanced NPC cell proliferation, migration, and invasion. In vivo experiments confirmed that silencing PRELID2 markedly suppressed the growth of subcutaneous xenograft tumors in nude mice. RNA-seq and functional rescue validation revealed that PRELID2 positively regulates the expression of thioredoxin domain-containing protein 12 (TXNDC12), increasing intracellular GSH levels. The accumulation of GSH enhances GPX4 activity, effectively inhibiting ferroptosis in NPC cells and ultimately promoting tumor progression. PRELID2 promotes NPC by upregulating TXNDC12 to sustain GSH levels, thereby enhancing GPX4 activity, inhibiting ferroptosis, and driving tumor growth. Suggest PRELID2 as a potential prognostic biomarker and therapeutic target for NPC.
Expression of Glycoprotein B (gB) Correlates With Poor Prognosis in Nasopharyngeal Carcinoma.
The Epstein-Barr virus (EBV) has two life cycles: latent and lytic. Previously, the latent cycle had been considered more relevant to EBV-associated epithelial malignancies, including nasopharyngeal carcinoma (NPC), whereas the lytic cycle, which ultimately leads to the death of host cells, had not been considered. However, recent studies have revealed that abortive lytic infections, in which the lytic cycle halts midway, avoids host cell death and contributes to tumorigenesis and tumor growth. However, the progression of the lytic cycle in NPC and its association with viral replication remain unclear. This study aimed to perform morphological analyses of EBV-positive NPC cell lines and clinical NPC biopsy samples using transmission electron microscopy, NanoSuit-correlative light and electron microscopy, and scanning ion conductance microscopy. Virion-like particles were observed in lytically induced EBV-positive NPC cell lines using time-lapse imaging to capture their release. These particles were also detected in clinical NPC samples using electron microscopy. Immunohistochemical analysis with the glycoprotein B (gB) antibody revealed a strong association between gB expression and poor prognosis. In conclusion, lytic infections with EBV replication occur in NPC, and the frequency of EBV replication is significantly associated with poor prognosis.
Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma.
It remains uncertain which Epstein-Barr virus (EBV)-related biomarkers provide the most reliable diagnostic performance for suspected nasopharyngeal carcinoma (NPC) in outpatient settings, especially regarding the novel anti-EBV BNLF2b total antibody (P85-Ab) assay. Clarifying their accuracy is critical to improving early detection and reducing misdiagnosis. To evaluate the diagnostic performance of the P85-Ab assay in suspected NPC in outpatient settings and compare it head-to-head with EBV viral capsid antigen (VCA)-immunoglobulin A (IgA), EBV early antigen (EA)-IgA, and EBV nuclear antigen 1 (EBNA1)-IgA. A prospective, multicenter cohort study was conducted between April 2021 and March 2024, with a median follow-up of 27.2 months in outpatient clinics across 5 medical centers in China. Key inclusion criteria comprised clinically suspected NPC. Data were analyzed from June 2025 to July 2025. P85-Ab was tested using chemiluminescent immunoassay. VCA-IgA, EA-IgA, and EBNA1-IgA were tested via enzyme-linked immunosorbent assays. Primary outcomes included sensitivity and specificity of P85-Ab. A total of 3795 eligible participants were consecutively recruited. After excluding individuals with low-quality samples or lost to follow-up, 3777 participants were included in the final analysis (1680 with NPC and 2097 without NPC). Among the 3777 evaluated participants (median [IQR] age, 49.0 [37.0-58.0] years; 65 % male), P85-Ab demonstrated superior diagnostic performance, with a sensitivity of 93.0% (95% CI, 91.6-94.0) and specificity of 97.3% (95% CI, 96.5-97.9). Other biomarkers showed lower sensitivity (ranging from 60.4% to 93.0%) and specificity (<90%). P85-Ab maintained high sensitivity among asymptomatic individuals (92.0%; 95% CI, 85.9-95.6) and those presenting with NPC-nonspecific symptoms (88.4%; 95% CI, 75.5-94.9), with no additional diagnostic benefit observed from the triplet-antibody strategy combining P85-Ab, VCA-IgA, and EBNA1-IgA. However, among participants with NPC-specific symptoms, the triplet-antibody strategy improved sensitivity compared with P85-Ab alone (95.9%; 95% CI, 94.8-96.8 vs 93.1%; 95% CI, 91.7-94.3; P < .001). In this cohort study, P85-Ab was a robust and accurate biomarker for suspected NPC in outpatient settings. P85-Ab alone may be suggested for populations with asymptomatic or NPC-nonspecific symptoms, and combining P85-Ab with VCA-IgA and EBNA1-IgA may be suggested for populations with NPC-specific symptoms.
Epstein-Barr virus drives nasopharyngeal carcinoma metastasis via RNA m5C modification of ICAM-1 mediated by NSUN2 and YBX3.
Epstein-Barr virus (EBV) is a critical epigenetic regulator in nasopharyngeal carcinoma (NPC) pathogenesis, primarily through well-established mechanisms involving DNA methylation and histone modifications. However, the contribution of RNA modifications, especially RNA 5-methylcytosine (m5C), to EBV-driven NPC progression remains largely unclear. Here, we performed RNA bisulfite sequencing (RNA-Bis-seq) on NPC cells and observed a global elevation in RNA m5C levels following EBV infection. Notably, EBV infection upregulated NSUN2, a known RNA m5C methyltransferase ("writer"), through LMP1-mediated activation of the NF-κB signaling pathway, leading to RNA m5C elevation. Functional assays confirmed that NSUN2 significantly enhances NPC cell migration and metastasis through its RNA m⁵C catalytic activity. Furthermore, we identified YBX3 as a novel RNA m⁵C-binding protein ("reader") that was simultaneously upregulated upon EBV infection. Mechanistically, NSUN2 catalyzed m5C modification on ICAM-1. Subsequently, YBX3 specifically recognized the modified site, recruiting PABPC1 through interacting with its cold shock domain and thereby enhancing ICAM-1 translation. Consistently, ICAM-1 overexpression effectively rescued the metastasis defects induced by NSUN2 knockdown. Additionally, we observed significant positive correlations among NSUN2, YBX3, and ICAM-1 expression levels in NPC tissues, with their expression strongly associated with tumor progression and poor prognosis. Together, our findings reveal the crucial role of RNA m5C modification in EBV-associated NPC progression, delineate the LMP1/NSUN2/YBX3/ICAM-1 signaling cascade, and suggest this regulatory axis as a potential therapeutic target for NPC.
A potent human neutralizing antibody targeting the receptor-binding site in the glycoprotein gp350 of Epstein-Barr virus.
The Epstein-Barr virus (EBV) is associated with multiple lymphoid malignancies and autoimmune diseases. The glycoprotein gp350, the most abundant envelope protein on the EBV virion surface, has been the primary target for the vaccine design. However, all the attempts have failed to prevent asymptomatic infection in clinical trials. This setback highlights an incomplete understanding of the immune response to gp350 and emphasizes the need for more comprehensive antibody studies. Here, we identified three human-derived anti-gp350 monoclonal antibodies from a nonimmune human scFv library. Of these, the S54 antibody exhibited a potent neutralizing activity against virus infection of Raji B cells. Using cryo-EM, we resolved the structure of the S54-gp350 complex, revealing that the S54 epitope substantially overlaps with the CR2 recognition site. Our findings elucidate the molecular mechanism by which anti-gp350 antibodies block EBV infection of B cells in vitro, providing valuable insights for antibody-based therapy and vaccine development.
Publicações recentes
[Corrigendum] MicroRNA‑122 acts as tumor suppressor by targeting TRIM29 and blocking the activity of PI3K/AKT signaling in nasopharyngeal carcinoma in vitro.
🥉 Relato de casoAlterations in NK cell subsets and the regulatory role of JAB1 in nasopharyngeal carcinoma with implications for tumor immunity and biomarker development.
Childhood Nasopharyngeal Carcinoma: A Rare Disease with Distinct Features and Favorable Prognosis.
📖 RevisãoDumbbell-Structured Plasmonic-Enhanced Optical Nanoprobes Boosting Photo-Magnetic-Acoustic Multimodal Imaging-Guided Photodynamic-Photothermal Synergistic Treatment and Immunogenic Death in Nasopharyngeal Carcinoma.
🥉 Relato de casoAssociation of Basal Thyroid Function with Clinical Outcomes in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with PD-L1 Inhibitor KL-A167: A Multicenter Post-hoc Analysis.
💬 Opinião📚 EuropePMC15.067 artigos no totalmostrando 196
Evaluation of the pterygoid process pneumatization and sclerosis with Vidian canal morphology using computed tomography: a comparative study in nasopharyngeal carcinoma patients and healthy controls.
Folia morphologicaA phase II randomized controlled trial of orally administered yeast-derived β-glucan for alleviating chemoradiotherapy-induced oral mucositis in nasopharyngeal carcinoma patients.
Frontiers in oncologyA modified homogeneity index for multi- target radiotherapy plans by subtracting high-dose subvolumes.
PeerJ[Analysis on hospitalization expenditures and influencing factors in nasopharyngeal cancer patients].
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhiDiagnostic performance analysis of two-gene methylation in urothelial carcinoma based on small-volume urine sample.
CancerInteraction between human oxoguanine glycosylase 1 gene polymorphisms and smoking status on nasopharyngeal carcinoma risk.
Journal of human geneticsNasopharyngeal mass containing B-cell small lymphocytic lymphoma in a human immunodeficiency virus-positive patient: A case report and review of the literature.
International journal of immunopathology and pharmacologyPrognostic value of early Epstein-Barr Virus DNA response in patients with locoregionally advanced nasopharyngeal carcinoma.
Oral oncologyComparison of the eighth and ninth editions of American Joint Committee on Cancer/Union for International Cancer Control staging for non-metastatic nasopharyngeal carcinoma.
Otolaryngologia polska = The Polish otolaryngologyInterpretable AI for treatment decision-making in immunoradiotherapy of locally advanced nasopharyngeal carcinoma.
Frontiers in oncologyClinical Outcomes and Individualized Seed Implantation Planning for Iodine-125 Seeds Brachytherapy in Lymph Node Metastases.
Journal of CancerIntegrin α5β1 in head and neck squamous cell carcinoma: expression, mechanisms, and clinical implications.
American journal of cancer researchSSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.
American journal of cancer researchPRELID2 promotes the progression of nasopharyngeal carcinoma by positively regulating the TXNDC12-GSH-GPX4 axis and inhibiting ferroptosis.
Cellular signallingPD-1/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.
MedicineExpression of Glycoprotein B (gB) Correlates With Poor Prognosis in Nasopharyngeal Carcinoma.
Cancer scienceNeoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma in Non-Endemic Regions: A Single-Arm Phase 2 Clinical Trial.
Cancer management and researchThe dual regulatory role of METTL14-mediated m6A modification in tumorigenesis and its underlying mechanisms.
Frontiers in oncologyDiagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma.
JAMA oncologyEffectiveness of Streptococcus salivarius probiotics on alleviating radiation-induced oral mucositis via inflammatory and microecological modulation: a prospective pragmatic interventional study in nasopharyngeal carcinoma.
Frontiers in immunologyEpstein-Barr virus drives nasopharyngeal carcinoma metastasis via RNA m5C modification of ICAM-1 mediated by NSUN2 and YBX3.
Cell death and differentiationIdentifying key risk factors for thrombocytopenia in patients undergoing radical chemoradiotherapy for nasopharyngeal cancer: a retrospective study.
Frontiers in oncologyPFAS and adipokines: Decoding their roles in the risk of breast nodules and breast cancer.
Environmental researchPrevention and management of radiation dermatitis for patients with nasopharyngeal carcinoma: a best practice implementation project.
BMC nursingNasopharyngeal carcinoma radiation-induced sarcoma in the skull base: a retrospective follow-up cohort study.
BMC surgeryGender disparities in the global burden of nasopharyngeal carcinoma: persistence and evolution of male predominance.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryThe value of time-dependent diffusion MRI in nasopharyngeal carcinoma: correlation with prognostic factors.
European radiologyA potent human neutralizing antibody targeting the receptor-binding site in the glycoprotein gp350 of Epstein-Barr virus.
Science China. Life sciencesBreaking the shackles of morphology: a novel perspective on immunotherapy evaluation for nasopharyngeal carcinoma using multimodal imaging and radiomics - a review.
Nuclear medicine communicationsMicronests in Tumor Stroma is a Prognostic Classifier in Nasopharyngeal Carcinoma.
The American journal of surgical pathologyPatterns of regional recurrences after treatment of nasopharyngeal carcinoma.
Radiation oncology (London, England)A selective enrichment and specific probe terminal mediated strategy for highly sensitive detection of microRNAs.
Nature communicationsFineST: contrastive learning integrates histology and spatial transcriptomics for nuclei-resolved ligand-receptor analysis.
Nature communicationsAnti-Hu paraneoplastic syndrome with gastrointestinal dysmotility associated with nasopharyngeal squamous cell carcinoma and small bowel adenocarcinoma.
BMJ case reportsPosition-Guided Nasopharyngeal Irrigation for Post-Radiotherapy Ulcer Care in Nasopharyngeal Carcinoma.
Journal of visualized experiments : JoVEIndustry update January 2026.
Therapeutic deliveryBrain abscess following acute otitis media in a nasopharyngeal carcinoma survivor: a case report.
International journal of surgery case reportsEfficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel Compared to Docetaxel Plus Nedaplatin as Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis.
Cancer management and researchDeep Learning-Based Videomics for Automatic Segmentation in Endoscopic Endonasal Surgery.
Annali italiani di chirurgiaLINC-AC092535.5 regulates MICAL2 mRNA level to inhibit p53-mediated ferroptosis in nasopharyngeal carcinoma.
OncogeneCombined Real-time Liquid Biopsy with TNM Stage to Guide Induction Chemotherapy Cycles in Nasopharyngeal Carcinoma: A Development and Validation Study.
International journal of radiation oncology, biology, physicsNasopharynx on Cone-beam Computed Tomography.
International dental journalLack of De-Intensification Models for Female Head and Neck Cancer Patients With Favorable Prognosis.
Cancer medicineDiagnostic and Economic Evaluation of [18F]FDG PET/CT Versus MRI for Lymph Node Staging in Nasopharyngeal Carcinoma: Implications for Individualized Upper-Neck-Only Irradiation.
Journal of clinical medicineHigh VRK2 expression level predicts unfavorable survival outcomes in nasopharyngeal carcinoma.
BMC cancerPrecision management of radiotherapy interruption in locoregionally advanced nasopharyngeal carcinoma: Induction chemotherapy counteracts the survival impact in high-risk patients defined by a novel model.
Translational oncologyLimitations of quality-of-life assessment and long-term side effects in nasopharyngeal carcinoma: a narrative review.
Oral oncologyPKM2 Deficiency Results in Reduced Proliferation of Nasopharyngeal Carcinoma Cells by Deactivation of Nrf2-HO-1-GSH Signaling.
Applied biochemistry and biotechnology68Ga-FAPI PET/CT in Nasopharyngeal Carcinoma: A Paradigm Shift in Imaging or Just Another Tool?
Radiology. Imaging cancerHELLS inhibits autophagy‑dependent ferroptosis in nasopharyngeal carcinoma by modulating the Nrf2/HO‑1/GPX4 pathway.
International journal of molecular medicineThe correlation between olfactory bulb volume and T&T odor threshold: a systematic review and meta-analysis.
Brain imaging and behaviorDeveloping a segmentation cascade deep learning network based on automated prompts.
Quantitative imaging in medicine and surgeryA pediatric nasopharyngeal carcinoma masquerading as Kimura disease: a rare case report from Nepal.
International journal of surgery case reportsBioinformatics identification of adenosylhomocysteinase (AHCY) as a regulator of ferroptosis in nasopharyngeal carcinoma cells via the Hippo-Yes-associated protein (Hippo-YAP) pathway.
Translational cancer researchMulti-parameter magnetic resonance imaging (MRI) deep learning radiomics predicts complete response after induction immunochemotherapy in locally advanced nasopharyngeal carcinoma.
Translational cancer researchThe roles and pathways of Hsa_circ_0000285 in cancer: a potential target for cancer therapy.
Cell divisionAssessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinoma.
Infectious agents and cancerRisk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.
Naturem⁶A-modified circMELK regulates nasopharyngeal carcinoma progression via a YTHDF1/circMELK-miR-4775-HMGA2 feedback loop.
Molecular immunologyChanges of F-18 fluorodeoxyglucose positron emission tomography/computed tomography textural features in temporal lobe after radiotherapy for nasopharyngeal carcinoma.
International journal of radiation biologyCross-technique transfer learning to predict the dose distribution for radiotherapy planning based on a limited sample size.
Medical physicsHarnessing the immune microenvironment: advances in nasopharyngeal carcinoma immunotherapy.
Cell death discoveryA Telemedicine App for Nonrigid Facial Rehabilitation Training Enhanced by Efficient Fully Convolutional Neural Network With Residual Network (EffiFCNN-ResNet) to Improve Accessibility for Patients With Nasopharyngeal Carcinoma Cancer: Randomized Controlled Trial.
JMIR mHealth and uHealthPrediction of treatment outcome in nasopharyngeal carcinoma patients.
BMC cancerTOLLIP targets GSDME-NT-carrying endocytic vesicles for autophagy to regulate pyroptosis and chemotherapy efficacy.
Nature cell biologyImpact of PDCA cycle-driven nutritional support on serum biomarkers and quality of life in nasopharyngeal carcinoma patients undergoing radiotherapy.
Journal of medical biochemistryCadonilimab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a step forward for bispecific immunotherapy?
Chinese clinical oncologyThe evaluation value of multiparametric imaging technology (MULTIPLEX) for grading and molecular subtyping of diffuse glioma patients.
Clinical radiologyThe 2025 Westlake Autumn Symposium for Al Proteomics and Virtual Cell.
Genomics, proteomics & bioinformaticsIntegrated bioinformatics analysis and experimental validation reveal Pevonedistat as a promising therapeutic agent modulating the CRL4-DTL-p21/p53 axis in nasopharyngeal carcinoma.
HereditasA nutritional risk index-based nomogram for predicting prognosis and identifying induction chemotherapy beneficiaries in nasopharyngeal carcinoma.
Scientific reportsDevelopment of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyRecent highlights and breakthroughs in immunotherapy for head and neck cancers.
Current opinion in oncologyCirculating Epstein-Barr virus DNA as a precision biomarker in nasopharyngeal carcinoma: from risk stratification to real-time treatment adaptation and disease surveillance.
Current opinion in oncologyAdvances in immunotherapy and targeted therapy for nasopharyngeal carcinoma: Current progress and combined approaches (Review).
Oncology reportsBrain Metastasis in Nasopharyngeal Carcinoma: A Case Report.
Case reports in oncologyNext-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy.
Frontiers in oncologyEfficacy, safety, and survival outcomes of radiotherapy combined with nimotuzumab following induction chemotherapy in locally advanced head and neck cancer.
Frontiers in oncologyMultimodal intervention for sarcopenia in nasopharyngeal carcinoma patients undergoing definitive treatment: a pilot randomized controlled trial protocol.
Nutrition journalBecotatug Vedotin: First Approval.
DrugsPre-treatment peripheral absolute monocyte count predicts metastatic progression and survival outcomes in treatment-naive non-metastatic nasopharyngeal carcinoma.
Frontiers in oncologySynergistic carcinogenesis of the nasopharyngeal microbiome and Epstein-Barr virus: mechanisms of metabolic reprogramming and immune evasion.
Frontiers in immunologyHLA class I signal peptide variation predicts strength of NKG2A+ NK cell response to missing-self and risk of human disease.
Nature immunologyTetrahydroberberine targets the bcl-2 promoter G-quadruplex to trigger mitochondrial apoptosis and inhibit nasopharyngeal carcinoma progression.
Chemico-biological interactionsComparative efficacy of tympanostomy tube insertion for secretory otitis media following radiotherapy for head and neck malignancies: a network meta-analysis.
Acta oto-laryngologicaSMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.
Cancer sciencePlasmonic platinum-tipped gold nanorods for tumor-targeted multimodal imaging diagnosis and NIR-II photothermal-catalytic-immuno synergetic therapy.
Journal of nanobiotechnologyPrediction of Neoadjuvant Chemotherapy Efficacy for Locally Advanced Nasopharyngeal Carcinoma Using MRI-Based Deep Learning Features Combined with Vision Transformer.
Academic radiologyCluster-Based MR Radiomics Model for Predicting Induction Chemotherapy Response in Nasopharyngeal Carcinoma.
Academic radiologyRT-SAM: Visual-Prompt Fusion and Uncertainty Enhancement for Nasopharyngeal Carcinoma Radiotherapy Target Delineation.
IEEE journal of biomedical and health informaticsComparative effectiveness of Volumetric Modulated Arc Therapy versus tomotherapy in locally advanced nasopharyngeal carcinoma: a propensity score-matched retrospective cohort study.
Radiation oncology (London, England)Autophagy hub genes mediate photodynamic therapy tolerance in nasopharyngeal carcinoma through cytoprotective autophagy and survival signaling.
Journal of molecular histologySwallowing-related outcomes and organ-at-risk dosimetry after proton versus photon radiotherapy in nasopharyngeal carcinoma.
Oral oncologyRegarding "Endoscopic surgery versus conservative treatment in nasopharyngeal carcinoma patients with nasopharyngeal necrosis": the potential confounding role of nutritional support.
RhinologyCandesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses.
EXCLI journalThe global landscape of particle beam radiotherapy trials over the past 15 years.
Cancer pathogenesis and therapyNonlinear association of serum uric acid and C-peptide with arterial stiffness in patients with type 2 diabetes: a real-world study.
Frontiers in endocrinologyPseudouridine synthases upregulate 5'-tRF-Lys to inhibit YPEL3 and drive malignant progression in nasopharyngeal carcinoma.
Cellular & molecular biology lettersLncRNA Gm16023 limits M1 macrophage-mediated hyperglycemia-exacerbated septic intestinal injury via miR-377-3p/Sirt1 axis.
Molecular therapy : the journal of the American Society of Gene TherapyPredicting Macrophage Spatial Localization from Single-Cell Transcriptomes to Uncover Disease Mechanisms.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)Role of Prognostic Nutritional Index and C-Reactive Protein/Albumin Ratio in Prognosis of Locally Advanced Nasopharyngeal Carcinoma.
Medicina (Kaunas, Lithuania)Extracellular Vesicles: A Multidimensional Role in the Occurrence and Development of Nasopharyngeal Carcinoma.
BiomoleculesNasopharyngeal Carcinoma at the Virology Precision Oncology Nexus: Decoding Molecular Alterations for Early Intervention and Therapeutic Innovation.
BiomoleculesHumanistic nursing care and quality of life in patients with nasopharyngeal carcinoma: a prospective observational study.
BMC nursingPedicled Inferior Turbinate-Nasal Floor and Septal Mucoperiosteal Flap Resurfacing for PRNN.
The LaryngoscopeEfficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.
Oral oncologyFirst-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.
JAMA oncologyPredicting induction chemotherapy response based on tumor-stroma ratio and pretreatment synthetic MRI in nasopharyngeal carcinoma.
European radiology experimentalPredictive Modeling of Treatment-Related Thyroid Dysfunction and Prognostic Implication in Advanced Nasopharyngeal Carcinoma With PD-1 Inhibitors.
The oncologistPD-1 inhibitors combined with induction chemotherapy followed by chemoradiotherapy in HPV-negative locally advanced head and neck squamous cell carcinoma: a real-world study.
Cancer immunology, immunotherapy : CIIThe ubiquitin-proteasome system is an important driver of EBV-associated nasopharyngeal carcinoma progression: a meta-analysis of transcriptomic data.
Scientific reportsIntegrative computational and experimental analysis identifies MEK-mediated carcinogenic effects of bisphenol A and diethyl phthalate in head and neck cancer.
Ecotoxicology and environmental safetyA Deep Dive Into Oncogenic Viruses Understanding Their Role in Cancer and Approaches for Prevention.
Reviews in medical virologyLactate-induced miR-7-5p/TRIM33 reprograms metabolic flux to suppress tumor growth and viral reactivation.
Molecular therapy : the journal of the American Society of Gene TherapyA survey to evaluate the knowledge of Syrian dental students about oral manifestation of systemic diseases: A cross-sectional study.
MedicineNonmetastatic nasopharyngeal carcinoma: in search of safer therapies.
Lancet regional health. AmericasComparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma.
International journal of cancerA Multimodal fusion model for predicting nasopharyngeal necrosis after re-irradiation in recurrent nasopharyngeal carcinoma.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicineBecotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial.
Med (New York, N.Y.)Elucidating EGCG' s targets in nasopharyngeal carcinoma through combined cell-based assays and transcriptomic sequencing.
Discover oncologyProspective Head-to-Head Comparison of 18F-FDG and 68Ga-FAPI PET/CT in De Novo and Recurrent Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Radiology. Imaging cancerA Rare Metastatic Squamous Cell Carcinoma of the Lacrimal Sac Originating from Nasopharyngeal Carcinoma: A Case Report.
Reports (MDPI)Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyEpidemiological study on nasopharyngeal cancer in Morocco: Case of the University Hospital Center Mohammed VI in Marrakech.
La Tunisie medicalePediatric Nasopharyngeal Carcinoma (NPC).
Current oncology reportsMETTL14 modulates the nasopharyngeal carcinoma microenvironment via m6A-modified YWHAH identified through single-cell and machine learning analyses.
Frontiers in immunologyCorrigendum to "Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy". [Radiother Oncol. 190 (2024) 109985].
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyLow-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial.
Oral oncologySEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoNetwork analysis of symptom clusters and core symptom changes in nasopharyngeal cancer survivors: a longitudinal study.
Journal of cancer survivorship : research and practicePotential of non-specific blood biomarkers combined with EBV-specific antibodies for triaging in nasopharyngeal carcinoma screening.
Scientific reportsSafety and Efficacy of Salvage Treatment for Recurrent Nasopharyngeal Carcinoma: A Single-Center Retrospective Study Over 10 Years.
Cancer medicinePalmitoylation modification of SPI1 promotes nasopharyngeal carcinoma radioresistance through inhibiting c-CBL-mediated ubiquitination and degradation.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyThe regional-control of prophylactic irradiation dose reduction of level Va in nasopharyngeal carcinoma (NPC).
Radiation oncology (London, England)Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma.
Med (New York, N.Y.)Research on EBV-miR-BART17-5p targeted Inhibition of ARID1A expression to regulate nasopharyngeal carcinoma dedifferentiation.
Cancer cell internationalMulti-institutional deep learning for GTV segmentation and survival prediction in nasopharyngeal carcinoma.
BMC medical imagingMalnutrition-related symptom clusters and quality of life in nasopharyngeal carcinoma patients during radiotherapy: a network analysis.
BMC cancerAn 18F-FDG PET/CT-based radiomics nomogram for predicting progression-free survival in nasopharyngeal carcinoma: A retrospective cohort study.
MedicineInteractions between hematological biomarkers of virus infection and immune cells in mediating distant metastasis in nasopharyngeal carcinoma: insights into prognosis and induction chemotherapy administration.
Radiology and oncologyGeneralization of the Conformity Index for Multi-Target Radiotherapy Plans.
CancersComprehensive Characterization of Stem Cell Landscape Identifies Novel Stemness-Relevant Genes for Nasopharyngeal Carcinoma Therapy.
CancersPrognostic factors and treatment outcomes in nasopharyngeal carcinoma patients with liver metastasis.
American journal of translational researchLong-term outcomes and patient profiles following intensity-modulated radio-chemotherapy for nasopharyngeal cancer in a nonendemic region.
Frontiers in oncologyInhibition of radiotherapy sensitivity in nasopharyngeal carcinoma via the long non-coding RNA RHPN1-AS1.
Translational cancer researchOptimizing the therapeutic ratio: a narrative review of de-escalation and response-adapted strategies in series including human papillomavirus negative head and neck cancer.
Translational cancer research[Comprehensive rehabilitation management of swallowing dysfunction after radiotherapy and chemotherapy for nasopharyngeal carcinoma].
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery[Integrated multitask visual-guided system for nasopharyngeal carcinoma detection using nasopharyngeal endoscopy: a retrospective multicenter study].
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgeryA machine learning-based predictive model for radiosensitivity in nasopharyngeal carcinoma utilizing serum proteomics.
Journal of translational medicineA Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.
Clinical case reportsUndifferentiated Nasopharyngeal Carcinoma in Low- and Middle-Income Countries: Clinical, Molecular, and Health-System-Related Challenges.
CureusImmunotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized clinical trials.
Therapeutic advances in medical oncologyDual-activated fluorescent probe for the study of the mechanism of SO2 and NO in cisplatin resistance of nasopharyngeal carcinoma.
RSC advancesZNF844 Suppresses Invasion and Metastasis in Nasopharyngeal Carcinoma by Inhibiting the PI3K-AKT Signaling Pathway.
Cancer scienceFinal survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.
Nature communicationsSDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers.
GutStandard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
BMJ (Clinical research ed.)CD38 degrades MAVS through mitophagy to inhibit type I interferon secretion in nasopharyngeal carcinoma cells and impairs CD8+T cell-mediated anti-tumor immunity.
Nature communicationsIntegrin α6 Targeted Tumor Theranostics.
Phenomics (Cham, Switzerland)Lactoferrin inhibits anoikis-resistance and metastasis of nasopharyngeal carcinoma cells via the AKT signaling pathway.
International journal of clinical and experimental pathologyMultimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma.
European journal of nuclear medicine and molecular imagingDevelopment and validation of prognostic nomograms based on peripheral blood T-cell counts and their dynamic changes for patients with nasopharyngeal carcinoma receiving radiotherapy.
Translational oncologyAddressing Etiological Factors of Nasopharyngeal Carcinoma in Kenyan Mountains.
Ear, nose, & throat journalNeutrophils in nasopharyngeal carcinoma: from mechanisms to therapeutics.
Journal of translational medicineIncidence and spectrum of immune-related adverse events in nasopharyngeal carcinoma patients treated with immune checkpoint inhibitors.
Med (New York, N.Y.)Improving prediction accuracy of radiation-induced temporal lobe injury in nasopharyngeal carcinoma using ADC-based deep learning and dosiomics.
BMC cancerPrognostic nomogram for patients with HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade.
ESMO openGenetic associations of LXN polymorphisms with toxicities of platinum-based concurrent chemoradiotherapy of nasopharyngeal carcinoma.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerEpstein-Barr Virus Infection at Single-Cell Resolution.
Journal of medical virologyFOLR1 Mediated by ITCH Promotes Paclitaxel Resistance by Suppressing Pyroptosis in Nasopharyngeal Carcinoma.
Archiv der PharmazieBCAT1-elicited branched-chain amino acid catabolism fosters neutrophil-mediated pan-metastasis in pancreatic cancer.
Molecular therapy : the journal of the American Society of Gene TherapyFusobacterium nucleatum manipulates host autophagy to promote its intracellular survival and treatment resistance in nasopharyngeal carcinoma.
Molecular cancer[Yiqi Jiedu Formula inhibits proliferation, invasion and migration of nasopharyngeal carcinoma cells by inhibiting the AKT1/GLUT1 signaling pathway].
Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityAndrogen receptor may promote tumor progression via TTF-1/EGFR pathway in metastatic nasopharyngeal carcinoma.
Translational oncologyUSP18 orchestrates malignant progression in nasopharyngeal carcinoma through UBR5-driven attenuation of p53 signaling.
International immunopharmacologyRefining M1-Stage Stratification in De Novo Metastatic Nasopharyngeal Carcinoma Using 18F-FDG PET/CT: Preliminary Evidence.
Clinical nuclear medicineThe Biology and Clinical Utility of EBV Monitoring in Blood.
Current topics in microbiology and immunologyAnalysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122.
Cancer medicineThe value of nasopharyngeal brush versus plasma EBV DNA detection in diagnosing local recurrence of nasopharyngeal carcinoma.
International journal of cancerArtificial intelligence-assisted real-time nasopharyngeal cancer diagnostic model enhances rhinologist performance: a prospective multi-reader study.
Annals of medicineA broadly protective antibody targeting gammaherpesvirus gB.
NatureComputed Tomography (CT) Guided Implantation of a Totally Implantable Venous Access Port (TIVAP) through Subclavian Vein.
Journal of visualized experiments : JoVEDose-guided individualized planning target volume margin optimization in nasopharyngeal carcinoma: a retrospective megavoltage computed tomography-based cumulative analysis.
Frontiers in oncologyEndopharyngeal Ultrasound-Guided Transpharyngeal Needle Aspiration for Confirming Retropharyngeal Lymph Nodes' Metastasis among Nasopharyngeal Carcinoma Patients.
Cancer communications (London, England)MADAT: Missing-aware dynamic adaptive transformer model for medical prognosis prediction with incomplete multimodal data.
Medical image analysisMRI-based deep learning model predicts recurrent nasopharyngeal carcinoma in post-radiation nasopharyngeal necrosis.
Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging SocietyFive-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.
JAMA oncologyFerritin as a novel predictive index for nasopharyngeal carcinoma survival and therapeutic efficacy of different chemotherapy regimens.
World journal of clinical oncologyPrognostic value of serum uric acid levels following radiotherapy and chemotherapy in nasopharyngeal carcinoma.
Molecular and clinical oncologyNon-Gaussian diffusion MRI using CTRW and FROC models for early treatment response assessment in nasopharyngeal carcinoma.
BMC medical imagingM $^{3}$ SegNet: A Multi-Modal and Multi-Branch Framework for Nasopharyngeal Carcinoma Segmentation in Radiotherapy Planning.
IEEE journal of biomedical and health informaticsAkt/mTOR pathway-mediated CCNA1 regulation of radiotherapy resistance in nasopharyngeal carcinoma.
Cellular oncology (Dordrecht, Netherlands)deltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types.
Clinical and translational medicineComparison of Local Control and Toxicity in T4 Nasopharyngeal Carcinoma Patients Treated with Induction Chemotherapy and Intensity-Modulated Radiotherapy: Conventional vs. Hyperfractionated Regimens.
Medicina (Kaunas, Lithuania)Overcoming chemoresistance in nasopharyngeal carcinoma: minocycline as a mitochondrial translation inhibitor.
Discover oncologyEfficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.
Cancer immunology, immunotherapy : CIIAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Carcinoma nasofaríngeo.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Carcinoma nasofaríngeo
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Ainda não achamos doenças com sintomas parecidos o suficiente.
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- PRELID2 promotes the progression of nasopharyngeal carcinoma by positively regulating the TXNDC12-GSH-GPX4 axis and inhibiting ferroptosis.
- Expression of Glycoprotein B (gB) Correlates With Poor Prognosis in Nasopharyngeal Carcinoma.
- Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma.
- Epstein-Barr virus drives nasopharyngeal carcinoma metastasis via RNA m5C modification of ICAM-1 mediated by NSUN2 and YBX3.
- A potent human neutralizing antibody targeting the receptor-binding site in the glycoprotein gp350 of Epstein-Barr virus.
- [Corrigendum] MicroRNA‑122 acts as tumor suppressor by targeting TRIM29 and blocking the activity of PI3K/AKT signaling in nasopharyngeal carcinoma in vitro.
- Alterations in NK cell subsets and the regulatory role of JAB1 in nasopharyngeal carcinoma with implications for tumor immunity and biomarker development.
- Childhood Nasopharyngeal Carcinoma: A Rare Disease with Distinct Features and Favorable Prognosis.
- Dumbbell-Structured Plasmonic-Enhanced Optical Nanoprobes Boosting Photo-Magnetic-Acoustic Multimodal Imaging-Guided Photodynamic-Photothermal Synergistic Treatment and Immunogenic Death in Nasopharyngeal Carcinoma.
- Association of Basal Thyroid Function with Clinical Outcomes in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Treated with PD-L1 Inhibitor KL-A167: A Multicenter Post-hoc Analysis.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:150(Orphanet)
- MONDO:0015459(MONDO)
- GARD:7163(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q1693598(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
